분석
~95%
저장 온도
2-8°C
SMILES string
OC(=O)\C=C\C(O)=O.COc1cc(N)c(Cl)cc1C(=O)NC2CCN(CC2)Cc3ccccc3
InChI
1S/C20H24ClN3O2.C4H4O4/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14;5-3(6)1-2-4(7)8/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25);1-2H,(H,5,6)(H,7,8)/b;2-1+
InChI key
BCVIWCRZYPHHMQ-WLHGVMLRSA-N
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
Eyeshields, Gloves, type N95 (US)
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
[Acute laryngeal dystonia due to clebopride simulating allergic reaction].
Medicina clinica, 129(6), 238-239 (2007-08-07)
Clinical neuropharmacology, 32(2), 107-108 (2009-06-11)
Dystonic reactions produce twisting and repetitive movements or abnormal posturing. Severe dystonic reactions have been shown to occur in concert with numerous medications. This report details the case of a patient who developed hemifacial dystonia as acute side reaction from
Partial least-squares regression for the quantitation of pharmaceutical dosages in control analyses.
Journal of pharmaceutical and biomedical analysis, 15(3), 329-338 (1996-12-01)
A spectrophotometric method for the simultaneous determination of the active principle and a flavouring agent in syrups containing additional excipients is proposed. The calibration matrix must include all the variability expected in the samples and this is achieved using laboratory-made
Movement disorders : official journal of the Movement Disorder Society, 19(4), 482-484 (2004-04-13)
We report on a patient who presented with a progressive supranuclear palsy (PSP) syndrome while receiving clebopride (CLB), a prokinetic drug with central antidopaminergic properties. The clinical and neurophysiological signs progressively disappeared after CLB withdrawal. To our knowledge, this is
Developmental psychobiology, 29(8), 653-666 (1996-12-01)
D1- and D2-like antagonist-induced catalepsy and dorsal immobility were studied in pups (Day 10) and weanlings (Days 20, 28, or 35) that received intraventricular injection of 6-OHDA (50 micrograms/hemisphere) or its vehicle solution or postnatal Day 3. The ability of
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.